Burning Rock Announces Results of 2024 Annual General Meeting

Core Insights - Burning Rock Biotech Limited successfully passed all shareholder resolutions at its 2024 annual general meeting, including the appointment of Ernst & Young Hua Ming LLP as auditor for the fiscal year ending December 31, 2024 [1] - The re-election of directors Yusheng Han and Gang Lu was also approved by shareholders [1] - Directors were authorized to take necessary actions to implement the resolutions [1] Company Overview - Burning Rock Biotech Limited focuses on next generation sequencing (NGS) technology in precision oncology, aiming to enhance cancer treatment and early detection [2] - The company's business includes NGS-based therapy selection testing for late-stage cancer patients and cancer early detection, which has progressed to clinical validation [2]